aspirin and fradafiban

aspirin has been researched along with fradafiban in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (66.67)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Byrne, A; Crean, P; Fitzgerald, DJ; Maher, M; Moran, N; Walsh, N	1
Bode, C; Kohler, B; Kübler, W; Moser, M; Nordt, T; Peter, K; Salbach, P; Schwarz, M; Ylänne, J	1
Byrne, A; Cox, D; Crean, P; Fitzgerald, DJ; Kearney, D	1

Trials

2 trial(s) available for aspirin and fradafiban

Article	Year
Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty. Arteriosclerosis, thrombosis, and vascular biology, 1997, Volume: 17, Issue:11 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biphenyl Compounds; Bleeding Time; Cell Division; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinogen; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Muscle, Smooth, Vascular; P-Selectin; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombosis; Thromboxane A2; Thromboxane B2; Vasoconstriction	1997
Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. Journal of the American College of Cardiology, 2004, Feb-18, Volume: 43, Issue:4 Topics: Angioplasty, Balloon, Coronary; Aspirin; Biphenyl Compounds; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprost; Epoprostenol; Female; Humans; Isoenzymes; Male; Membrane Proteins; Middle Aged; Peroxidases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prostaglandin-Endoperoxide Synthases; Pyrrolidines; Sulfonamides; Thromboxane A2	2004

Article

Year

Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty.

Arteriosclerosis, thrombosis, and vascular biology, 1997, Volume: 17, Issue:11

Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biphenyl Compounds; Bleeding Time; Cell Division; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinogen; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Muscle, Smooth, Vascular; P-Selectin; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombosis; Thromboxane A2; Thromboxane B2; Vasoconstriction

1997

Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor.

Journal of the American College of Cardiology, 2004, Feb-18, Volume: 43, Issue:4

Topics: Angioplasty, Balloon, Coronary; Aspirin; Biphenyl Compounds; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprost; Epoprostenol; Female; Humans; Isoenzymes; Male; Membrane Proteins; Middle Aged; Peroxidases; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prostaglandin-Endoperoxide Synthases; Pyrrolidines; Sulfonamides; Thromboxane A2

2004

Other Studies

1 other study(ies) available for aspirin and fradafiban

Article	Year
Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood, 1998, Nov-01, Volume: 92, Issue:9 Topics: Abciximab; Animals; Antibodies, Monoclonal; Aspirin; Binding, Competitive; Biphenyl Compounds; CHO Cells; Cricetinae; Disintegrins; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Indomethacin; Mice; Oligopeptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Pyrrolidines; Recombinant Fusion Proteins	1998

Article

Year

Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.

Blood, 1998, Nov-01, Volume: 92, Issue:9

Topics: Abciximab; Animals; Antibodies, Monoclonal; Aspirin; Binding, Competitive; Biphenyl Compounds; CHO Cells; Cricetinae; Disintegrins; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Indomethacin; Mice; Oligopeptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Protein Binding; Pyrrolidines; Recombinant Fusion Proteins

1998